| __timestamp | Alkermes plc | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 5078000000 |
| Thursday, January 1, 2015 | 311558000 | 4717000000 |
| Friday, January 1, 2016 | 374130000 | 5096000000 |
| Sunday, January 1, 2017 | 421578000 | 4986000000 |
| Monday, January 1, 2018 | 526408000 | 4214000000 |
| Tuesday, January 1, 2019 | 599449000 | 3806000000 |
| Wednesday, January 1, 2020 | 538827000 | 3671000000 |
| Friday, January 1, 2021 | 560977000 | 3528000000 |
| Saturday, January 1, 2022 | 605747000 | 3445000000 |
| Sunday, January 1, 2023 | 689751000 | 3498000000 |
| Monday, January 1, 2024 | 645238000 | 3702000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Teva Pharmaceutical Industries Limited and Alkermes plc have shown contrasting approaches to handling these costs. From 2014 to 2023, Alkermes plc has demonstrated a steady increase in SG&A expenses, rising by approximately 245%, from $200 million to nearly $690 million. This growth reflects their strategic investments in marketing and administration to bolster their market presence.
Conversely, Teva has managed to reduce its SG&A expenses by about 31%, from $5.08 billion in 2014 to $3.50 billion in 2023. This significant reduction highlights Teva's focus on cost efficiency and operational optimization. As these two companies continue to navigate the pharmaceutical landscape, their differing strategies in managing SG&A costs offer valuable insights into their long-term business models.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Alkermes plc Trends and Insights
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Alkermes plc and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Alkermes plc or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Alkermes plc vs Veracyte, Inc. Trends and Insights